BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
October 04, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Oct. 04, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Presents Data Demonstrating Efficiency of Parallel TCR Capture and Bioinformatics Platforms at 7th Annual CAR-TCR Summit
September 26, 2022 09:45 ET
|
BlueSphere Bio
PITTSBURGH, Sept. 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present at the 7th Annual CAR-TCR Summit
September 19, 2022 10:30 ET
|
BlueSphere Bio
PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention
June 13, 2022 11:40 ET
|
BlueSphere Bio
PITTSBURGH, June 13, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Data to be Presented at the 2022 Joint ASTCT + EBMT Basic and Translational Scientific Retreat
May 25, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, May 25, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients...
BlueSphere Bio Appoints Robert Keefe, Ph.D. as Chief Development Officer
April 26, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, April 26, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting
April 08, 2022 13:05 ET
|
BlueSphere Bio
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against the minor histocompatibility antigen HA-1, from a single donor Data support the broad potential of...
BlueSphere Bio Data to be Presented at the 2022 American Association for Cancer Research Annual Meeting
March 15, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, March 15, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present at the BIO CEO & Investor Conference
February 08, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Feb. 08, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for...